Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | CDK9 | P50750 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431630 | 0.86 | SMN1; SMN2 (0.56) | L3MBTL1CNR1EPHX1SMN1; SMN2TP53 | |
| SCHEMBL10263293 | 0.83 | CNR1 (0.54) | L3MBTL1CNR1EPHX1SMN1; SMN2TP53 | |
| SCHEMBL10202733 | 0.83 | SMN1; SMN2 (0.54) | L3MBTL1CNR1EPHX1SMN1; SMN2TP53 | |
| SCHEMBL1116578 | 0.82 | L3MBTL1 (0.55) | L3MBTL1CNR1SMN1; SMN2TP53EPHX2 | |
| SCHEMBL16920271 | 0.82 | NPC1 (0.60) | L3MBTL1CNR1SMN1; SMN2TP53RAB9A | |
| SCHEMBL19075440 | 0.82 | CNR1 (0.52) | L3MBTL1CNR1EPHX1SMN1; SMN2TP53 | |
| SCHEMBL12127864 | 0.81 | SMN1; SMN2 (0.59) | L3MBTL1CNR1EPHX1SMN1; SMN2TP53 | |
| SCHEMBL71711 | 0.80 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2RAB9AMAPTGAA | |
| SCHEMBL16588344 | 0.80 | RAB9A (0.61) | L3MBTL1SMN1; SMN2RAB9ANPC1HTT | |
| SCHEMBL20725429 | 0.80 | RAB9A (0.55) | L3MBTL1SMN1; SMN2TP53RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859583-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-20120035153-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035153-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, CDK1 | L3MBTL1 3793/4885CNR1 911/4885EPHX1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.